Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
59 hedge funds and large institutions have $86.6M invested in Kezar Life Sciences in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 6 closing their positions.
135% more capital invested
Capital invested by funds: $36.8M → $86.6M (+$49.8M)
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
7% more funds holding
Funds holding: 55 → 59 (+4)
0.41% more ownership
Funds ownership: 4.79% → 5.2% (+0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$9.13M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$8.01M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$6.92M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5.89M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.74M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$909K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$493K |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$363K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$304K |
KZR Hedge Fund Activity: Q1 2020 in Review
59 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2020, worth a combined $86.6M — up 135% from $36.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KZR positions and 6 closed out — a net gain of 4 holders — while 31 added to existing stakes and 16 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $9.13M. The largest seller was Fidelity Investments, cutting an estimated $1.74M.
- 59 institutional investors held Kezar Life Sciences (KZR) as of Q1 2020, up from 55 in Q4 2019.
- Funds reported $86.6M of Kezar Life Sciences stock for Q1 2020, up 135% quarter-over-quarter.
- 10 funds opened new Kezar Life Sciences positions in Q1 2020 and 6 closed out, a net change of +4 holders.
- The largest Kezar Life Sciences buyer in Q1 2020 was Victory Capital Management, an estimated $9.13M added.
- The largest Kezar Life Sciences seller in Q1 2020 was Fidelity Investments, an estimated $1.74M sold.
Based on aggregated 13F filings for Q1 2020.